OPTHF
Optimi Health Corp.·Consumer Defensive
0.22
1.136%(−0.00)
Market OpenLast Updated: — ET
52W L: $0.1052W H: $0.29
OPTHF NEWS
newsfilecorp.com
Mar 16
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed with the United States Securities and Exchange Commission (the "SEC"), in connection with its proposed listing on the Nasdaq Capital Market ("Nasdaq"). Joseph Gunnar & Co., LLC is acting as sole book-running manager for the proposed Offering.
newsfilecorp.com
Feb 26
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated Framework Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme. The clinical administration follows the Company's first psilocybin shipment of 2026 and represents the early rollout of Optimi's finished drug product across authorised clinics operating within Australia's nationally regulated access framework.
newsfilecorp.com
Feb 19
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Naturally-Derived 5 mg Psilocybin Capsules Mark the Company's Second Drug in Market Under Australia's Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of patients diagnosed with treatment-resistant depression (TRD) under Australia's Authorised Prescriber Scheme. The shipment represents Optimi's second finished drug product supplied into Australia's Authorised Prescriber Scheme, alongside the Company's 40 mg and 60 mg MDMA capsules for post-traumatic stress disorder (PTSD).
feeds.newsfilecorp.com
Feb 19
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 19. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder
feeds.newsfilecorp.com
Feb 16
Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken
Vancouver, British Columbia--(Newsfile Corp. - Montag, 16. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi"
feeds.newsfilecorp.com
Feb 9
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or
